Series C : Yuanta Investment Korea Co., Ltd. / KB-Solidus Investment / KDB Bank / E&Investment / SBI Investment Korea Co., Ltd. / Live Cell Instrument / CEO of the DB, Nam Ho Kim
10
Launch of NanoCalibur™ and Patent Application
10
Lipid nanoparticle manufacturingtechnology encapsulating mRNAs and ASOs Patent Granted
06
Established Mepsgenus Inc. Silicon Valley Office
04
Designated as Military Manpower Administration’s Office
02
ProMEPS™ Patent Granted
01
MST-MPA126’s Patent Granted
2023
11
Launch of ProMEPS™ (MEPS-AMS, a fully automated robotic system for MPS modeling)
11
Award from the Minister of Trade, Industry, and Energy (MOTIE), ‘Innovative and Fast-Growing Bio Company'
11
Confirmed non-clinical efficacy of MG-GHC24 (Nanomedicine for Glioblastoma) in patient tissues
07
Signing of a Joint Research Agreement about brain tumors (GBM) with ChaBio Hospital
07
Signing of a Cooperative Agreement about evaluation and validation of the Microphysiological System with K-BIO Health
05
Signing of an Agreement to develop extracellular matrix biomaterials with Cellartgen
05
Signing of MOU for Research Services with CRO companies; Corestem Chemon and Woojung Bio
05
MG-PE3’s Patent Registration(Korea)
04
MG-PP3 and MG-GTX13’s Patent Applications
01
Signing of a Collaborative Research Agreement with Georgia Tech, USA
2022
12
Initiating nanoparticle manufacturing and mass production business
07
Series B : KDB Bank / DONG-A SOCIO HOLDINGS / KOLON Investment / KIWOOM Securities Co., Ltd. / CEO of the DB, Nam Ho Kim
06
LNP mass production technology patent application (Microfluidic technology)
06
MG-G101 patent application
03
MEPS-TBC cryopreservation patent grant
2021
11
MG-PE3 PCT application
09
MEPS-TBC, Manufactured & Released
08
Series A (Bridge) : Korea Investment Partners Co., Ltd / SBI Investment Korea Co., Ltd. / KNOTUS Co., Ltd. / Tiumbio Co., Ltd
04
MG-PE3 patent granted in Republic of Korea
03
Started CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease - 1st Drug efficacy
02
Kicked off MEPS-BBB research service using new drug candidates with pharmaceutical companies
01
Expansion & relocation of the office, R&D center, and production facility (Hanyang Tower, 12, Beobwon-ro-11-gil, Songpa-gu, Seoul, Rep. of Korea)
2020
12
Finished PK/PD CRO evaluation of MG-PE3, new drug candidate for Alzheimer's disease
